JARDIANCE Market Size, Forecast, and Emerging Insight - 2032

"JARDIANCE Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about JARDIANCE for myocardial infarction in the seven major markets. A detailed picture of the JARDIANCE for myocardial infarction in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the JARDIANCE for myocardial infarction. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the JARDIANCE market forecast analysis for myocardial infarction in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.

Drug Summary:

JARDIANCE (Empagliflozin) is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for glucose re-absorption in the kidney. It is marketed under the brand name JARDIANCE and is the first type 2 diabetes medicine to include cardiovascular death risk reduction data on the label in several countries. Empagliflozin lowers blood glucose levels by preventing glucose re-absorption in the kidneys and increasing the amount of glucose excreted in the urine. It has a relatively long duration of action requiring only once-daily dosing. As its mechanism of action is contingent on the renal excretion of glucose, empagliflozin may be held in cases of acute kidney injury and/or discontinued in patients who develop chronic renal disease.

Currently, the company is conducting a Phase III (EMPACT-MI) study. EMPACT-MI (EMPAgliflozin for the prevention of chronic heart failure and mortality after an AMI) is a streamlined, randomized, blinded, placebo-controlled, multicenter trial exploring the efficacy and safety of JARDIANCE in adults hospitalized with an acute MI with data anticipated in 2023. The trial is part of the EMPOWER clinical trial program, the broadest and most comprehensive of any SGLT2 inhibitor, exploring the impact of JARDIANCE on people's lives across the spectrum of cardio-renal-metabolic conditions.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the JARDIANCE description, mechanism of action, dosage and administration, research and development activities in myocardial infarction.
• Elaborated details on JARDIANCE regulatory milestones and other development activities have been provided in this report.
• The report also highlights the JARDIANCE research and development activities in myocardial infarction across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around JARDIANCE.
• The report contains forecasted sales of JARDIANCE for myocardial infarction till 2032.
• Comprehensive coverage of the late-stage emerging therapies for myocardial infarction.
• The report also features the SWOT analysis with analyst views for JARDIANCE in myocardial infarction.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

JARDIANCE Analytical Perspective by DelveInsight

• In-depth JARDIANCE Market Assessment

This report provides a detailed market assessment of JARDIANCE for myocardial infarction in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• JARDIANCE Clinical Assessment

The report provides the clinical trials information of JARDIANCE for myocardial infarction covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for myocardial infarction is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence JARDIANCE dominance.
• Other emerging products for myocardial infarction are expected to give tough market competition to JARDIANCE and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of JARDIANCE in myocardial infarction.
• Our in-depth analysis of the forecasted sales data of JARDIANCE from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the JARDIANCE in myocardial infarction.

Key Questions:

• What is the product type, route of administration and mechanism of action of JARDIANCE?
• What is the clinical trial status of the study related to JARDIANCE in myocardial infarction and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the JARDIANCE development?
• What are the key designations that have been granted to JARDIANCE for myocardial infarction?
• What is the forecasted market scenario of JARDIANCE for myocardial infarction?
• What are the forecasted sales of JARDIANCE in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to JARDIANCE for myocardial infarction?
• Which are the late-stage emerging therapies under development for the treatment of myocardial infarction?